Emma Clark, WCO21: Novel Technologies for Skeletal Assessment
touchIMMUNOLOGY joins Professor Emma Clark (University of Bristol, UK) at WCO21 to discuss the current limitations of osteoporosis diagnosis and the latest novel technologies for skeletal assessment.
1. Why is the diagnosis of osteoporosis so challenging? (00:16-02:13)
2. What are the strengths and limitations of currently available tools and services to diagnose osteoporosis? (02:13-04:28)
3. What are the most exciting novel technologies for skeletal assessment? (04:28-05:57)
4. What are the major barriers for implementation of novel technologies and how might these be overcome? (05:57-10:18)
Disclosures: Emma Clark is Vice Chair of the Novel Technologies working group, part of the Royal Osteoporosis Bone Research Academy.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the WCO21 Annual Meeting.
Share this Video
Related Videos In Rheumatic Diseases
Machine-learning models as predictors of fractures in osteoporosis: Giovanni Adami, WCO-IOF-ESCEO 2023
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!